memorandum - Cree Health
Transcription
memorandum - Cree Health
MEMORANDUM To : Physicians, Nurses, Lab technicians and Pharmacists in Eeyou Istchee From : Dr. France Morin, Consultant Physician on Sexually Transmitted Infections Dr. Kianoush Dehghani, Coordinator of Infectious Diseases Cree Public Health, Region 18 Date: April 16 2013 RE: Syphilis : Up-to-date measures to improve Regional surveillance STATEMENT OF PURPOSE: The purpose of this memorandum is to recommend improved surveillance for syphilis in our region. REGIONAL CONTEXT: 1) Our Region continues to be at “HIGH RISK” for sexually transmitted infections (STI), mainly for Chlamydia and Gonorrhea with 7-11 times higher infection rates than the rest of Quebec. 2) We have had three cases of syphilis in our Region within the last 5 years. So far, 2 cases have been reported to the Cree Public Health in 2013. Moreover, recently we were made aware of significantly increased rate of syphilis in other adjacent Regions. 3) Syphilis is a disease that is not always easy to diagnose, and is associated with important morbidity & mortality, including congenital syphilis, and neurosyphilis & cardiovascular complications of tertiary syphilis. Also, sores associated with syphilis increase the risk of HIV transmission by 2-5 times. WHAT TO DO: 1) Promoting healthy sexuality in the community: e.g. consistent condom use 2) Screening of asymptomatic individuals (see new recommendations regarding syphilis screening for our region): a. Population screening: e.g. screening of pregnant women b. individuals at risk screening: e.g. screening of individuals with history of high risk sexual behavior 3) Testing of symptomatic individuals (see appendix 1) 4) Contact tracing and contact management of all individuals who test positive for syphilis (see Appendix 3) Page 1 sur 13 5) Reporting all individuals with a positive test for syphilis (i.e. MADO) to the public health department of Region 18 (see appendix 2) 6) Appropriate antibiotic treatment and follow-up of individuals with syphilis (please see appendix 1). 7) Rehabilitation & long-term care of individuals affected by disabling tertiary syphilis and congenital syphilis. REGIONAL NEW RECOMMENDATIONS ON SCREENING OF ASYMPTOMATIC INDIVIDUALS USING THE “RPR” TEST: 1) POPULATION-BASED SCREENING: a. Screening of pregnant women at the beginning (i.e. during the first prenatal visit), AND at week 28 of pregnancy (Note: the test at 28 weeks of gestation can be done concomitantly with the blood test for glucose tolerance, and screening for gonorrhea and Chlamydia) 2) SCREENING OF INDIVIDUALS AT RISK: a. All individuals who test positive for gonorrhea should be tested for syphilis (Note: they should also be offered HIV testing with consent & counseling). b. Other individuals with identified risk factors, including: i. Individuals with multiple sexual partners : 1. Defined as individuals with more than 3 partners during the past year. ii. Individuals who have had sexual relations with a partner originating from « endemic » regions or countries for STI and HIV (Note : Please contact a designated public health physician** if you have a question about disease frequencies in different jurisdictions); iii. Men who have sex with men (MSM); iv. Sex workers; v. Street youths; vi. Individuals who have contracted gonorrhea, syphilis, HIV, hepatitis B vii. and/ or hepatitis C infection(s) during the last year; Individuals who have had unprotected sexual relationship with other individual(s) with above characteristics. 3) All sexual contacts of a patient with confirmed syphilis infection have to be evaluated based on the incubation & contagious periods (see Appendix 1), by clinical examination and an RPR test (see Appendix 1). If the initial RPR test proves negative in an identified sexual contact, the test should be repeated in 3 (three) weeks (see Appendix 1). Page 2 sur 13 a. All pregnant syphilis contacts have to be reported immediately to the designated public health physicians**. b. All symptomatic (see Appendix 1) contacts have to be reported immediately to the designated public health physicians**. c. Unless otherwise indicated by the designated public health physicians** or the designated ID specialists**, the clinicians should “wait” for the results of the RPR and the treponemal tests “prior” to treating the patient for syphilis. Attention: If the results of the RPR are not available in 1 (one) week after the blood sample was sent to the lab, please contact the designated public health physician** to follow-up. 4) All individuals who ask for screening for STI, even without reporting any of the above risk factors after pre-test counseling, should be tested. Page 3 sur 13 APPENDIX 1. CLINICAL PRESENTATION, TESTING AND TREATMENT OF SYPHILIS: FOR MORE INFORMATION PLEASE REFER TO THE INESS WEBSITE AT: HTTP://WWW.INESSS.QC.CA/FILEADMIN/DOC/INESSS/OUTILS/GUIDES_ITSS/SYPHILIS_GUIDE_ITSS_17JAN.PDF 1. PRIMARY SYPHILIS : CHANCRE The chancre lesion appears anywhere from 10 to 90 days after the infectious contact (on average after 3 weeks). The lesion can be found on any inoculation site(s), but mainly involve the genital, anorectal and/ or oro-pharyngeal areas. The chancre lesion starts as a “papule” (usually only one), and eventually develops to an ulcer. The superficial ulcerative lesion is often painless (unless super-infected), with regular contour and indurated base, and measures up to 1 cm in diameter. Pain-less local adenopathy may be present. The lesion often regresses spontaneously in 3 to 8 weeks. The chancre lesion can go unnoticed. Attention : Whenever a genital, ano-rectal and/ or oro-pharyngeal ulcer-like lesion is observed (including those that are pain-less), a viral culture has to be taken to rule out “herpes”. Page 4 sur 13 2. SECONDARY SYPHILIS : SKIN RASH Often appears 2 to 12 weeks, sometimes a few months, after the chancre lesion has healed. Often is accompanied by « flu-like » symptoms. It consists of a generalized diffuse maculo-papular and non-pruritic rash (can also affect the palms of hands and soles of feet) Over time, the lesions can coalesce to form flat condylomas (i.e. condyloma lata). The rash goes away spontaneously in 3 to 12 weeks. The rash can go unnoticed. Note: When you observe a diffuse rash in an adult, consider« syphilis » in your differential diagnosis! 3. LATENT (HIDDEN) SYPHILIS: ASYMPTOMATIC Medical history and serological testing(s) help the clinician to diagnose and classify latent syphilis : Early latent syphilis: Less than one year after the onset of syphilis infection; the affected person is considered contagious. Page 5 sur 13 Late latency syphilis: More than one year after the onset of the syphilis infection. Late latency syphilis is not considered contagious, however, infected pregnant women can still transmit the infection vertically to their fetus. 4. TERTIARY SYPHILIS Tertiary syphilis appears in about 40% of individuals who did not receive appropriate treatment for syphilis, approximately 5 to 30 years after the spontaneous healing of the chancre lesion. Tertiary (late) syphilis is slowly progressive and may affect any organ. The disease is generally not thought to be infectious at this stage. Manifestations may include the following: Cardiovascular: aortic aneurysm, aortic regurgitation etc. Neurosyphilis : dementia, altered mental status, peripheral neuropathy, incontinence, focal neurologic findings such as hearing and vision loss etc. Other: syphilitic gumma , paroxysmal cold hemoglobinuria, irreversible end organ damage etc. PLEASE NOTE : Individuals who are HIV-positive can develop symptoms very different from the symptoms described above. HIV can also increase the chances of developing syphilis with neurological involvement. Please consult a designated ID specialist** for more information. 5. CONGENITAL SYPHILIS : Congenital syphilis is caused by trans-placental (i.e. vertical) transmission of syphilis infection. The transmission rate approaches 90% if the mother has untreated primary or secondary syphilis. Fetal infection can develop at any time during gestation. Manifestations are defined as early if they appear in the first 2 years of life and late if they develop after age 2 years. According to a Centre for Disease Control (CDC U.S.) report, untreated syphilis, especially early syphilis, during pregnancy can lead to deafness, neurologic impairment, bone deformities, stillbirth, and neonatal death. Page 6 sur 13 6. CONTAGIOUSNESS (INFECTIOUS PERIOD) Primary syphilis Secondary syphilis Contagious Period Early latent Syphilis Late latency syphilis Tertiary Non-contagious Period 7. DIAGNOSTIC TESTING : In our Region, the RPR (Rapid Plasma Reagin) test has replaced the VDRL as the primary non-treponemal diagnostic test for syphilis. An RPR serological test has to be done when a patient presents with signs and symptoms that are suggestive of syphilis. If the RPR test of a symptomatic patient proves negative, it has to be repeated in 3 weeks, in order to reduce the probability of a false negative result (e.g. due to “window period” of primary syphilis). All the positive (or in doubt) RPR results are automatically sent to the laboratoire provincial de santé publique (LSPQ) for confirmation with a treponemal test (i.e. TP-PA). Consult a designated public health physician** and/ or a designated ID specialist** for EVERY symptomatic case suspected of having syphilis, immediately. Moreover, the “contacts” of a confirmed syphilis patient should also be tested by the RPR test. Again, if the RPR test for a contact of a confirmed syphilis patient proves negative, it should be repeated in 3 weeks to reduce the probability of a false negative result. Page 7 sur 13 7.Screening test for asymptomatic cases : In our Region, the RPR has replaced the VDRL test as the primary non-treponemal test for screening asymptomatic individuals for syphilis. All the positive (or in doubt) RPR results are automatically sent to the laboratoire provincial de santé publique (LSPQ) for confirmation with a treponemal test (i.e. TP-PA). 8. TREATMENT : First choice: Penicillin G benzathine*, 2,4 millions units applied intramuscularly (IM). This is a prolonged-action penicillin. *ATTENTION : Not to be confused with penicillin G sodique, a short-acting penicillin that is inadequate for treating syphilis. The required number of treatments and the type of antibiotics used depend on the patient’s stage of syphilis and other factors (e.g. HIV status, allergy to penicillin, pregnancy & breastfeeding etc.). Please consult a designated public health physician** and/ or a designated ID specialist** prior to treating ANY case of syphilis (including for the treatment of pregnant women, congenital syphilis, individuals with HIV and those with known allergy to penicillin). Treatment for syphilis is provided free charge for all qualified Cree & Inuit residents of Region 18. For questions on medication coverage for non-qualified patients, please contact the pharmacist in Chisasibi Hospital. For individuals with primary and secondary syphilis a serological follow-up by quantitative RPR test is required to evaluate the response to treatment, at 3,6 and 12 months after the treatment (Please discuss the post-treatment monitoring of cases with latent syphilis, tertiary syphilis, neurosyphilis, congenital syphilis and HIV infected individuals with designated ID specialist physicians**). Please discuss the titer values of post-treatment RPR with the designated ID specialist at MUHC**. Page 8 sur 13 **Designated Physicians: The designated public health physicians for sexually transmitted infections at the Cree Public Health are: Dr. Kianoush Dehghani: Telephone: 514-861-2352 extension 74237 Email: kianoush.dehghani@mcgill.ca OR kianoush.dehghani@ssss.gouv.qc.ca Fax: 514-861-5206 Dr. France Morin: Telephone: 450-248-0686 or 514-861-2352 Email: france.morin.chb@ssss.gouv.qc.ca Fax: 450-248-3752 The designated infectious disease specialists at the MUHC and CHB are: Dr. Vivian Loo and Dr. Pierre Rene (Note: this assignment will change in the near future, and new ID physicians will be assigned to this position). They can be paged through the MUHC general operator at 514-934-1934 extension 53333 from 8:00 to 16:00 hr. Outside business hours or when above physicians are not available, you may contact the ID specialist on-call at the Royal Victoria Hospital. Page 9 sur 13 APPENDIX 2. DECLARABLE DISEASES OR MALADIE À DÉCLARATION OBLIGATOIRE (MADO) SYPHILIS IS A MADO THAT HAS TO BE DECLARED BY: The treating physician AND The laboratory To obtain a declaration form, see the attached form and/ or refer to the website : http://publications.msss.gouv.qc.ca/acrobat/f/documentation/preventioncontrole/AS-770.pdf The MADO declaration form has to be faxed « immediately » to the Cree Public Health Department (Region 18) at: (514) 862-5206 1. Note: For the « nosologique » definition of syphilis, please consult the reference document published by the Ministère de la Santé et des Services sociaux of Quebec (MSSS), which is available at: http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2012/12-268-03W.pdf Page 10 sur 13 Page 11 sur 13 Appendix 3. Les partenaires à joindre en fonction de la période de contagiogité (Source : refernces 4 & 7-9) Les intervalles indiqués ci-après sont ceux habituellement recommandés. Ils constituent des intervalles minimaux. Comme il est difficile de déterminer le moment précis où l’infection a été contractée et que les périodes d’incubation sont généralement des estimations pouvant comporter une marge d’incertitude, il peut être justifié, dans certaines situations, de prolonger la période indiquée Infectionss Partenaire à joindre Actions • les partenaires qui ont eu un contact sexuel avec la personne infectée dans les 60 jours précédant le début des Infection génitale à Chlamydia trachomatis symptômes ou le moment du diagnostic; et • s’il n’y a aucun partenaire sexuel dans les 60 jours précédant le début des symptômes ou le moment du infection gonococcique diagnostic, le plus récent partenaire sexuel de la personne infectée; •les lespartenaires partenairesqui quiont onteueuun uncontact contactsexuel sexuelavec aveclalapersonne personneinfectée infectée: avant que celle-ci ait terminé son traitement ou moins de 7 jours après un traitement unidose; • jusqu’à 3 mois avant le début des symptômes; • les partenaires qui ont eu un contact sexuel avec la personne infectée qui présente des symptômes. • pendant la durée des symptômes. Syphilis Primaire Si la date du début des symptômes est inconnue ou incertaine2, les partenaires qui ont eu un contact sexuel avec la personne infectée jusqu’à 4 mois et une semaine avant le moment du diagnostic. Secondaire les partenaires qui ont eu un contact sexuel avec la personne infectée : Traitement épidémiologique1. Évaluation des indications de dépistage des ITSS. Évaluation des indications de dépistage des a u t r e s ITSS. Si dernier contact sexuel ≤ 90 jours : traitement épidémiologique1. Si dernier contact sexuel > 90 jours : traitement selon le résultat des tests. • jusqu’à 6 mois avant le début des symptômes; • pendant la durée des symptômes. Si la date du début des symptômes est inconnue ou incertaine2, les partenaires qui ont eu un contact sexuel avec la personne infectée jusqu’à 8 mois avant le moment du diagnostic. latente précoce les partenaires qui ont eu un contact sexuel avec la personne infectée jusqu’à 1 an avant le moment du diagnostic. latente tardive les partenaires présents ou passés qui ont eu une relation de longue durée avec la personne infectée devraient être dirigés vers les services appropriés pour un examen clinique et sérologique. latente tardive titrage ≥1 : 32 Traitement selon le résultat des tests. Évaluation des indications de dépistage des ITSS. Si le titre du test non tréponémique est élevé (1 : 32 ou plus), il est plus prudent de faire comme s’il s’agissait Idem à la syphilis primaire, d’une syphilis latente précoce et de rechercher tous les partenaires de la dernière année. secondaire et latente précoce. 1. Traitement administré d’emblée sans attendre le résultat de l’analyse de laboratoire et même si le partenaire est asymptomatique 2. Si la date de début des symptômes est inconnue ou incertaine, mais que des symptômes de syphilis sont présents au moment ou un professionnel de la santé fait le diagnostic, on ajoute une pérode correspondant à la durée maximale des symptômes. Page 12 sur 13 Refernces: 1) 2) 3) 4) 5) 6) 7) Dre V. Loo & Dr P. Rene (consultant microbiologists, CUSM & CHB), in-person consultation, March 2013. Syphilis Memorandum prepared by the DSP of Region 08 (l’Abitibi et Temiscaminque) February 2013. INESS: Guide ITSS – Syphilis. Website: http://www.inesss.qc.ca/fileadmin/doc/INESSS/Outils/Guides_ITSS/syphilis_GUIDE_ITSS_17jan.pdf. INSPQ. Janvier 2012. Canadian Guidelines on Sexually Transmitted Infections. Website: http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-10-eng.php. PHAC. Updated 2010. Maladie d’Origine Infectieuse : Definition Nosologique, Syphilis (p. 105). MSSS QC. 9 edition. Website : http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2012/12-268-03W.pdf. Juin 2012. CDC – Syphilies Factsheet. Website : http://www.cdc.gov/std/syphilis/STDFact-Syphilis-detailed.htm. Last updated 13 Feb 2013. Institut nationale de santé publique du Québec. Complément québécois. Lignes directrices canadiennes sur les infections transmissibles sexuellement édition 2006. 8) Ministre de la santé et des services sociaux (MSSS QC). Aide-mémoire à l’'intention des professionnels de l a santé. Intervention préventive auprès des personnes atteintes d'une infection transmissible sexuellement et auprès de leurs partenaires, pour briser la chaîne de transmission, traiter les partenaires. 2004 (page 8). 9) Régie régionale de la santé et des services sociaux de Montréal-Centre, et Régie régionale de la santé et des services sociaux de Laval. Évaluation d'un servicede soutien à la notification aux partenaires de personnes atteintes d'une maladie transmissible sexuellement (MTS) autre que /'infection auVIH, juin 1998. 10) Euerle B, & B.A. Cunha. Syphilis. Medscape. Updated Jan 6, 2013 11) Waseem M, & R. Steele. Pediatric Syphilis. Medscape. Updated April 1 2013. 12) MC Drouin. Facteurs de risqué et ITSS : à rechercher (Mise à jour des indication de dépistage). INSPQ (CALI). 27 Février 2013. 13) Institut nationale de santé publique du Québec. Complément québécois. Lignes directrices canadiennes sur les infections transmissibles sexuellement édition 2006, Québec, institut , 2007. 14) Ministre de la santé et des services sociaux. Aide-mémoire à l’'intention des professionnels de la santé. Intervention préventive auprès des personnes atteintes d'une infection transmissible sexuellement et auprès de leurs partenaires, pour briser la chaîne de transmission, traiter les partenaires, Québec, ministère de la santé et des Services sociaux, 2004, 8 p. 15) Régie régionale de la santé et des services sociaux de Montréal-Centre, et Régie régionale de la santé et des services sociaux de Laval. Évaluation d'un service de soutien à la notification aux partenaires de personnes atteintes d'une maladie transmissible sexuellement (MTS) autre que /'infection au VIH, juin 1998. Page 13 sur 13
Similar documents
Les infections sexuellement transmissibles - Infectio Saint
TPHA-LCR/Total LCR IgG TPHA-serum/Total serum IgG si>3: positif
More information